1. Jaeckle KA, Decker PA, Ballman KV, Flynn PJ, Giannini C, Scheithauer BW, et al. Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis. J Neurooncol. 2011; 104:253–259. PMID:
21153680.
2. Murphy ES, Leyrer CM, Parsons M, Suh JH, Chao ST, Yu JS, et al. Risk factors for malignant transformation of low-grade glioma. Int J Radiat Oncol Biol Phys. 2018; 100:965–971. PMID:
29485076.
3. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014; 343:189–193. PMID:
24336570.
4. Park CK, Park I, Lee S, Sun CH, Koh Y, Park SH, et al. Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas. Oncotarget. 2015; 6:43653–43666. PMID:
26524630.
5. Jung TY, Jung S, Moon JH, Kim IY, Moon KS, Jang WY. Early prognostic factors related to progression and malignant transformation of low-grade gliomas. Clin Neurol Neurosurg. 2011; 113:752–757. PMID:
21889256.
6. Babu R, Bagley JH, Park JG, Friedman AH, Adamson C. Low-grade astrocytomas: the prognostic value of fibrillary, gemistocytic, and protoplasmic tumor histology. J Neurosurg. 2013; 119:434–441. PMID:
23662821.
7. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23:1231–1251. PMID:
34185076.
8. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016; 131:803–820. PMID:
27157931.
9. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013; 19:764–772. PMID:
23209033.
10. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360:765–773. PMID:
19228619.
11. Gorovets D, Kannan K, Shen R, Kastenhuber ER, Islamdoust N, Campos C, et al. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clin Cancer Res. 2012; 18:2490–2501. PMID:
22415316.
12. Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015; 372:2499–2508. PMID:
26061753.
13. Kim YZ, Kim CY, Lim DH. The overview of practical guidelines for gliomas by KSNO, NCCN, and EANO. Brain Tumor Res Treat. 2022; 10:83–93. PMID:
35545827.
14. Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021; 18:170–186. PMID:
33293629.
15. Liu V, Wetzel EA, Eldred BSC, Zapanta Rinonos S, Prins TJ, Khanlou N, et al. A single-institution retrospective analysis of pathologically determined malignant transformation in IDH mutant glioma patients. Neurooncol Adv. 2023; 5:vdad036. PMID:
37152809.
16. Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol. 2004; 108:49–56. PMID:
15118874.
17. Tihan T, Vohra P, Berger MS, Keles GE. Definition and diagnostic implications of gemistocytic astrocytomas: a pathological perspective. J Neurooncol. 2006; 76:175–183. PMID:
16132490.
18. Watanabe K, Tachibana O, Yonekawa Y, Kleihues P, Ohgaki H. Role of gemistocytes in astrocytoma progression. Lab Invest. 1997; 76:277–284. PMID:
9042164.